CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Samsung Bioepis Co., Ltd. vs. Regeneron Pharmaceuticals, Inc.

๐Ÿ“ก 5G SEP โ€ข ETSI Declared

Explore the PTAB proceeding IPR2023-00739 filed by Samsung Bioepis Co., Ltd. on 2023-03-26. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2023-00739

Filing Date

2023-03-26

Accorded Filing Date

2023-03-27

Institution Decision Date

2023-10-20

Last Modified Date

2025-03-26

Proceeding Type

IPR

Termination Date

2024-07-30

Trial Status

Terminated-Adverse Judgment

Parties & Counsel

Patent Owner / Respondent

Patent Information

1 Patent Involved
Respondent Application Number 16397267
Respondent Patent Number 10888601
Legal Expiration Date
2039-04-29 Active (12.4 yrs remaining)
Injunction Viability (35 U.S.C. ยง 283) Active Threat
Respondent Inventor George D. YANCOPOULOS
Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Tribunal & APJ Panel Intelligence

Board Intelligence

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Decisions Rendered

3 Total

Proceeding Status

Terminated-Adverse Judgment

Administrative Patent Judges (APJ Panel)

Panel assignment tracked upon institution decision entry

Board Decisions & Rulings (3)

Request For Adverse Judgment After Institution 2024-07-30
Adverse judgment: post-institution
37 CFR 42.73
Institution Granted(Joined) 2024-01-16
Institution decision and grant of joinder, IPR2024-00201
37 CFR 42.122, 35 USC 314, 37 CFR 42.72, 35 USC 315
Institution Granted 2023-10-20
Institution Decision: Grant
35 USC 312, 35 USC 314

Address and Attorney/Agent Information

23 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name A&P - Regeneron (Prosecution)
Customer Number 191459
Address 601 Massachusetts Ave., NW, Washington, DC, 20001-3743, UNITED STATES

Attorney / Agent Information

Reg # Name Phone
41408 David Marsh +1 202-942-5068
48001 Thomas Triolo +1 914-847-1612
48921 Stephen Gaudet +1 914-847-7376
50370 Neil Miyamoto +1 914-847-7175
50437 Frank Cottingham +1 914-593-1116
58583 Brian Cocca +1 914-847-1421
58714 Ilona Gont +1 914-847-1304
59668 Brandon Schurter +1 914-847-7000

Global Patent Family Cross-Litigation Radar

CasLoc 360ยฐ Radar 18 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

๐Ÿ‡บ๐Ÿ‡ธ
U.S. District Courts Counterparts in force
๐Ÿ›๏ธ
USPTO PTAB Trials 9 proceedings
๐Ÿ‡ช๐Ÿ‡บ
Unified Patent Court (UPC) Counterparts in force
๐Ÿ‡ฉ๐Ÿ‡ช
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (18): ๐Ÿ‡บ๐Ÿ‡ธ US ๐ŸŒ PCT
Parallel Proceedings Across Jurisdictions (9 found):
PTAB: 9
USPTO PTAB Trial 2025-07-14
IPR2025-01269

Fresenius Kabi SwissBiosim, GmbH et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10828345)
Status: Institution Denied
USPTO PTAB Trial 2023-12-18
IPR2024-00298

Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11253572)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-12-14
IPR2024-00260

Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11253572)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-11-20
IPR2024-00201

Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc.

Asserted Patent
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-04-27
IPR2023-00884

Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11253572)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-02-10
IPR2023-00533

Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2023-02-10
IPR2023-00566

Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2023-02-10
IPR2023-00532

Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10130681)
Status: Final Written Decision
USPTO PTAB Trial 2023-01-06
IPR2023-00442

Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10130681)
Status: Final Written Decision
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP โ€ข ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 5G NR Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Samsung

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.

โœ“ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
โœ“ Right to demand global FRAND portfolio determination.
โœ“ Non-discrimination defense: check licensing terms offered to competing implementers.

Proceeding Documents

200
59

Order: Granting Patent Owners Motion to Expunge 37 C.F.R. sec. 42.56 ORDER

2024-10-08 FILING PARTY: BOARD
2043

Ex. 2043 - Manning Declaration - Redacted Exhibit

2024-09-04 FILING PARTY: PATENT OWNER
58

Patent Owner's Motion to Expunge MOTION

2024-09-04 FILING PARTY: PATENT OWNER
57

Adverse judgment: post-institution ADVRSJUDG

2024-07-30 FILING PARTY: BOARD
3003

Ex. 3003 Exhibit

2024-07-18 FILING PARTY: BOARD

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc